![ccr 8 ccr 8](https://ars.els-cdn.com/content/image/1-s2.0-S0045206820318587-ga1.jpg)
Integrating Harbour Mice ® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.įor further information, please refer to S. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE ®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. The Company’s proprietary antibody technology platforms Harbour Mice ® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. Please click the link below for the poster: Novel Monoclonal Antibodies (mAbs) Targeting Human CCR8 Provide Potential Candidates for Next Generation Cancer Immunotherapy “The success of generating antibodies against a difficult GPCR target further demonstrates the power and efficiency of HBM’s antibody discovery platforms” he added. Jingsong Wang said, the Founder, Chairman, and CEO of Harbour BioMed.
![ccr 8 ccr 8](https://media.biocompare.com/m/37/product/13085700-400x300.jpg)
We are excited to develop this candidate further into a therapy that could address multiple tumor types in the future” Dr. “The ability to modulate the tumor micro-environment with a target like CCR8, either by itself or in combination with other molecules is an extremely promising approach.
![ccr 8 ccr 8](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c3c6ae11-d663-4c41-b136-e1e2a98974aa/gr1_lrg.jpg)
Furthermore, this antibody blocked the binding of CCL1 to CCR8 thereby inhibiting CCL1-induced suppressive function of TIL-Tregs. It selectively targeted and depleted a subpopulation of tumor resident CCR8+ Tregs in the tumor microenvironment resulting in tumor growth inhibition, both as a single agent as well as in combination with anti-PD-1 antibody in preclinical setting. HBM used a combination of next generation technologies including Single B Cell Technology with advanced phage display and hybridoma platforms to successfully develop the anti-CCR8 monoclonal antibody. These results suggest CCR8 could potentially be a promising therapeutic target. High expression of CCR8 on Treg cells was first found to be associated with poor prognosis in breast cancer patients. The poster was presented through a voice-over presentation at the 16th PEGS Boston Summit (from August 31 to September 4, 2020).ĬCR8 is selectively up-regulated in tumor resident Treg cells in multiple solid tumors, but rarely observed on Treg cells in peripheral blood mononuclear cells (PBMCs) or other normal organs. HBM1022 was designed to target C-C chemokine receptor type 8 (CCR8), an extremely challenging G-protein coupled receptor (GPCR) with limited success in generating a cross-reactive antibodies in the past (cynomolgus and human). September, 2, 2020, Cambridge, MA, Rotterdam, NL, Shanghai, CN – Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, presented its newly discovered novel anti-human CCR8 mAbs (HBM1022) at the 16 th PEGS Boston Summit.